Analysts Set Guardant Health, Inc. (NASDAQ:GH) Price Target at $40.31

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seventeen ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and sixteen have issued a buy recommendation on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $40.31.

GH has been the topic of several analyst reports. Citigroup lifted their target price on shares of Guardant Health from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Thursday, August 8th. Bank of America lifted their target price on shares of Guardant Health from $28.00 to $40.00 and gave the stock a "buy" rating in a research note on Thursday, July 18th. Leerink Partners decreased their target price on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $45.00 to $48.00 and gave the stock an "overweight" rating in a research note on Thursday, August 8th. Finally, UBS Group lifted their price target on shares of Guardant Health from $32.00 to $40.00 and gave the company a "buy" rating in a report on Wednesday, August 21st.

Hedge Funds Weigh In On Guardant Health

A number of hedge funds have recently bought and sold shares of GH. Vanguard Group Inc. raised its position in Guardant Health by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 11,130,654 shares of the company's stock worth $301,084,000 after buying an additional 180,424 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new stake in shares of Guardant Health during the 1st quarter valued at about $273,000. Principal Financial Group Inc. increased its position in shares of Guardant Health by 1,649.4% during the 1st quarter. Principal Financial Group Inc. now owns 228,215 shares of the company's stock valued at $4,708,000 after purchasing an additional 215,170 shares during the last quarter. Baillie Gifford & Co. increased its position in shares of Guardant Health by 0.9% during the 1st quarter. Baillie Gifford & Co. now owns 6,232,104 shares of the company's stock valued at $128,568,000 after purchasing an additional 53,292 shares during the last quarter. Finally, Oak Ridge Investments LLC increased its position in shares of Guardant Health by 8.5% during the 1st quarter. Oak Ridge Investments LLC now owns 18,540 shares of the company's stock valued at $382,000 after purchasing an additional 1,451 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.

Guardant Health Price Performance

NASDAQ GH traded up $0.31 on Friday, reaching $20.51. 1,406,261 shares of the company's stock traded hands, compared to its average volume of 1,382,453. Guardant Health has a 12 month low of $15.81 and a 12 month high of $37.04. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07. The stock has a 50-day simple moving average of $23.74 and a 200 day simple moving average of $25.61. The stock has a market cap of $2.52 billion, a PE ratio of -5.01 and a beta of 1.11.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative net margin of 76.23% and a negative return on equity of 418.21%. The company had revenue of $177.24 million for the quarter, compared to analysts' expectations of $162.59 million. During the same period last year, the company posted ($0.67) EPS. The business's revenue for the quarter was up 29.2% compared to the same quarter last year. As a group, research analysts predict that Guardant Health will post -3.31 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.